(NASDAQ: RIGL) Rigel Pharmaceuticals's forecast annual revenue growth rate of 7.67% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Rigel Pharmaceuticals's revenue in 2025 is $203,077,000.On average, 4 Wall Street analysts forecast RIGL's revenue for 2025 to be $4,051,716,079, with the lowest RIGL revenue forecast at $3,644,188,885, and the highest RIGL revenue forecast at $4,450,771,741. On average, 4 Wall Street analysts forecast RIGL's revenue for 2026 to be $4,221,647,163, with the lowest RIGL revenue forecast at $3,960,709,656, and the highest RIGL revenue forecast at $4,655,768,536.
In 2027, RIGL is forecast to generate $4,567,478,722 in revenue, with the lowest revenue forecast at $4,432,184,412 and the highest revenue forecast at $4,791,062,846.